ALRUD advised Solopharm

ALRUD advised Solopharm

15 December 2016

ALRUD experts advised the pharmaceutical company Solopharm on the sale of a minority stake to Baring Vostok, one of the Russian leading investment funds. Solopharm is a unicorn startup, a market leader in the production of liquid sterile dosages in Russia, and the largest company in the Baring Vostok portfolio.

ALRUD experts also provided the client with support on various issues related to the construction and the commissioning of a new pharmaceutical plant as well as the acquisition of project financing.

The deal was one of the largest deals on the Russian pharmaceutical market in 2016.

The ALRUD team that worked on the project under the leadership of Alexander Zharskiy (Partner and Head of Corporate and M&A Practice) and Anton Dzhuplin (Partner of Corporate and Banking & Finance Practices) included representatives of the Corporate Practice: Counsel Oleg Ezhov and Associate Irina Kuyantseva.

We use cookies to offer better performance of the website and fulfill some other purposes specified in the Privacy Policy. By way of ticking the box you provide your consent to use of cookies. Otherwise, we will only use technical cookies, which are necessary for proper functioning of the website.